Insights from AR Gene Mutations

  • Grant Buchanan
  • Eleanor F. Need
  • Tina Bianco-Miotto
  • Norman M. Greenberg
  • Howard I. Scher
  • Margaret M. Centenera
  • Lisa M. Butler
  • Diane M. Robins
  • Wayne D. Tilley


The accumulation of somatic mutations on the background of natural germline variation is one of the fundamental mechanisms underpinning both disease and the development and progression of perhaps all tumors. For example, germline inactivating mutations in one allele of a tumor suppressor gene (TSG) (e.g., p53 or BRCA1) predisposes an individual to a lifetime of increased risk of cancer in particular tissues. In those cases, tumors commonly arise after somatic inactivation of the second TSG allele, and are often characterized by a younger age of onset and a more aggressive phenotype than tumors arising in the same tissues without a common or dominant genetic predisposition. A small proportion of prostate cancers do indeed occur in a hereditary manner, but it has been difficult to attribute inheritance and risk to a single gene. Even for the monoallelic androgen receptor (AR) gene on the X chromosome, which exhibits variously traits of an at-risk allele, oncogene, and mediator of prostate cancer progression and therapy resistance, inactivating germline variation in the AR is essentially nonexistent in this disease. Instead, germline AR variants often underpin the relatively common inherited syndrome of androgen insensitivity (AIS). In contrast, however, somatic variation of the AR is potentially a frequent event during tumor progression.

As a consequence of these complexities, unraveling the precise role of the AR at each stage of prostate cancer progression, and indeed in different prostatic compartments or populations of tumor cells is challenging. In this chapter, we detail how the identification and characterization of somatic AR variants arising in prostate cancer has provided crucial information on (1) the role of the receptor throughout disease etiology and the emergence of castrate-recurrent disease, (2) the fine functional subdomain structure of the AR, (3) the oncogenic potential of aberrant AR signaling, and (4) new approaches to targeting AR function in disease management.


Prostate Cancer Androgen Receptor Androgen Receptor Signaling Androgen Receptor Activity Androgen Receptor Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors acknowledge the contributions of Drs. Rene Chmelar and Guangzhou Han (Fred Hutchinson Cancer Research Center, University of Washington) and technical assistance of Ms. Joanna Treloar. The authors are supported by the Prostate Cancer Foundation of Australia (GB, ID#Y102), the National Health and Medical Research Council of Australia (WDT, ID#453662), The United States Department of Defense (WDT, ID#PC060443), and a SPORE Grant from the National Cancer Institute (DMR, NCI P50 CA69568). GB holds a National Health and Medical Research Council of Australia CJ Martin Biomedical Fellowship. EFN is a recipient of a Freemasons Foundation Postdoctoral Fellowship.


  1. AarnisaloP, SanttiH, PoukkaH, PalvimoJJ, JanneOA(1999)Transcription activating and repressing functions of the androgen receptor are differentially influenced by mutations in the deoxyribonucleic acid-binding domain. Endocrinology140:3097–3105PubMedGoogle Scholar
  2. AlenP, ClaessensF, VerhoevenG, RombautsW, PeetersB(1999)The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol19:6085–6097PubMedGoogle Scholar
  3. AnWG, SchulteTW, NeckersLM(2000)The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ11:355–360PubMedGoogle Scholar
  4. AskewEB, GampeRT, Jr, StanleyTB, FaggartJL, WilsonEM(2007)Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem282:25801–25816PubMedGoogle Scholar
  5. AuluckPK, ChanHY, TrojanowskiJQ, LeeVM, BoniniNM(2002)Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science295:865–868PubMedGoogle Scholar
  6. BalicI, GrahamST, TroyerDA, HigginsBA, PollockBH, Johnson-PaisTL, ThompsonIM, LeachRJ(2002)Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol168:2245–2248PubMedGoogle Scholar
  7. BeilinJ, BallEM, FavaloroJM, ZajacJD(2000)Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol25:85–96PubMedGoogle Scholar
  8. BennettCL, PriceDK, KimS, LiuD, JovanovicBD, NathanD, JohnsonME, MontgomeryJS, CudeK, BrockbankJC, SartorO, FiggWD(2002)Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol20:3599–3604PubMedGoogle Scholar
  9. BentelJM, TilleyWD(1996)Androgen receptors in prostate cancer. J Endocrinol151:1–11PubMedGoogle Scholar
  10. BerrevoetsCA, DoesburgP, SteketeeK, TrapmanJ, BrinkmannAO(1998)Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol12:1172–1183PubMedGoogle Scholar
  11. BlagosklonnyMV, ToretskyJ, BohenS, NeckersL(1996)Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A93:8379–8383PubMedGoogle Scholar
  12. BlancoJG, MinucciS, LuJ, YangXJ, WalkerKK, ChenH, EvansRM, NakataniY, OzatoK(1998)The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev12:1638–1651PubMedGoogle Scholar
  13. BohlCE, WuZ, MillerDD, BellCE, DaltonJT(2007)Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem282:13648–13655PubMedGoogle Scholar
  14. BoltonEC, SoAY, ChaivorapolC, HaqqCM, LiH, YamamotoKR(2007)Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev21:2005–2017PubMedGoogle Scholar
  15. BrodieJ, McEwanIJ(2005)Intra-domain communication between the N-terminal and DNA-binding domains of the androgen receptor: modulation of androgen response element DNA binding. J Mol Endocrinol34:603–615PubMedGoogle Scholar
  16. BruggenwirthHT, BoehmerAL, LobaccaroJM, ChicheL, SultanC, TrapmanJ, BrinkmannAO(1998)Substitution of Ala564 in the first zinc cluster of the deoxyribonucleic acid (DNA)-binding domain of the androgen receptor by Asp, Asn, or Leu exerts differential effects on DNA binding. Endocrinology139:103–110PubMedGoogle Scholar
  17. BuchananG, GreenbergNM, ScherHI, HarrisJM, MarshallVR, TilleyWD(2001a)Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res7:1273–1281Google Scholar
  18. BuchananG, IrvineRA, CoetzeeGA, TilleyWD(2001b)Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev20:207–223Google Scholar
  19. BuchananG, CraftPS, YangM, CheongA, PrescottJ, JiaL, CoetzeeGA, TilleyWD(2004)PC-3 cells with enhanced androgen receptor signaling: A model for clonal selection in prostate cancer. Prostate60:352–366PubMedGoogle Scholar
  20. BuchananG, RicciardelliC, HarrisJM, PrescottJ, YuZC, JiaL, ButlerLM, MarshallVR, ScherHI, GeraldWL, CoetzeeGA, TilleyWD(2007)Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res67:10087–10096PubMedGoogle Scholar
  21. BuchananG, TilleyWD(2000)Androgen receptor structure and function in prostate cancer. In: JJLi, JRDarling, SALi (eds.), Hormonal Carcinogenesis III, III edn, pp. 333–341. New York: Springer-VerlagGoogle Scholar
  22. BuchananG, YangM, CheongA, HarrisJM, IrvineRA, LambertPF, MooreNL, RaynorM, NeufingPJ, CoetzeeGA, TilleyWD(2004)Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet13:1677–1692PubMedGoogle Scholar
  23. BuchananG, YangM, NahmSJ, HanG, MooreN, BentelJM, MatusikRJ, HorsfallDJ, MarshallVR, GreenbergNM, TilleyWD(2000)Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol15:46–56Google Scholar
  24. ButlerLM, AgusDB, ScherHI, HigginsB, RoseA, Cordon-CardoC, ThalerHT, RifkindRA, MarksPA, RichonVM(2000)Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res60:5165–5170PubMedGoogle Scholar
  25. ButlerLM, CenteneraMM, NeufingPJ, BuchananG, ChoongCS, RicciardelliC, SaintK, LeeM, OchnikA, YangM, BrownMP, TilleyWD(2006)Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Mol Endocrinol20:1009–1024PubMedGoogle Scholar
  26. CallewaertL, Van TilborghN, ClaessensF(2006)Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res66:543–553PubMedGoogle Scholar
  27. CarducciMA, GilbertJ, BowlingMK, NoeD, EisenbergerMA, SinibaldiV, ZabelinaY, ChenTL, GrochowLB, DonehowerRC(2001)A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res7:3047–3055PubMedGoogle Scholar
  28. CeralineJ, CruchantMD, ErdmannE, ErbsP, KurtzJE, DuclosB, JacqminD, ChopinD, BergeratJP(2004)Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer108:152–157PubMedGoogle Scholar
  29. ChamberlainNL, WhitacreDC, MiesfeldRL(1996)Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain. J Biol Chem271:26772–26778PubMedGoogle Scholar
  30. ChangCY, McDonnellDP(2002)Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol16:647–660PubMedGoogle Scholar
  31. ChengH, SnoekR, GhaidiF, CoxME, RenniePS(2006)Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res66:10613–10620PubMedGoogle Scholar
  32. CheungJ, SmithDF(2000)Molecular chaperone interactions with steroid receptors: an update. Mol Endocrinol14:939–946PubMedGoogle Scholar
  33. Cheung-FlynnJ, PrapapanichV, CoxMB, RiggsDL, Suarez-QuianC, SmithDF(2005)Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol19:1654–1666PubMedGoogle Scholar
  34. ChmelarR, BuchananG, NeedEF, TilleyW, GreenbergNM(2007)Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer120:719–733PubMedGoogle Scholar
  35. CraftN, ShostakY, CareyM, SawyersCL(1999)A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med5:280–285PubMedGoogle Scholar
  36. CuligZ, HobischA, CronauerMV, RadmayrC, TrapmanJ, HittmairA, BartschG, KlockerH(1994)Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res54:5474–5478PubMedGoogle Scholar
  37. CuligZ, HobischA, HittmairA, PeterzielH, CatoAC, BartschG, KlockerH(1998)Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate35:63–70PubMedGoogle Scholar
  38. CuligZ, HobischA, BartschG, KlockerH(2000)Androgen receptor – an update of mechanisms of action in prostate cancer. Urol Res28:211–219PubMedGoogle Scholar
  39. CuligZ, BartschG, HobischA(2002)Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol197:231–238PubMedGoogle Scholar
  40. CuligZ, ComuzziB, SteinerH, BartschG, HobischA(2004)Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol92:265–271PubMedGoogle Scholar
  41. DotzlawH, MoehrenU, MinkS, CatoAC, Iniguez LluhiJA, BaniahmadA(2002)The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol16:661–673PubMedGoogle Scholar
  42. EdwardsA, HammondHA, JinL, CaskeyCT, ChakrabortyR(1992)Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics12:241–253PubMedGoogle Scholar
  43. EisemanJL, GuoJ, RamanathanRK, BelaniCP, SolitDB, ScherHI, IvySP, ZuhowskiEG, EgorinMJ(2007)Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clin Cancer Res13:2121–2127PubMedGoogle Scholar
  44. Estebanez-PerpinaE, ArnoldLA, NguyenP, RodriguesED, MarE, BatemanR, PallaiP, ShokatKM, BaxterJD, GuyRK, WebbP, FletterickRJ(2007)A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci U S A104:16074–16079PubMedGoogle Scholar
  45. FarlaP, HersmusR, GevertsB, MariPO, NiggAL, DubbinkHJ, TrapmanJ, HoutsmullerAB(2004)The androgen receptor ligand-binding domain stabilizes DNA binding in living cells. J Struct Biol147:50–61PubMedGoogle Scholar
  46. FeldmanBJ, FeldmanD(2001)The development of androgen-independent prostate cancer. Nat Rev1:34–45Google Scholar
  47. FonteV, KapulkinV, TaftA, FluetA, FriedmanD, LinkCD(2002)Interaction of intracellular beta amyloid peptide with chaperone proteins. Proc Natl Acad Sci U S A99:9439–9444PubMedGoogle Scholar
  48. FronsdalK, EngedalN, SlagsvoldT, SaatciogluF(1998)CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem273:31853–31859PubMedGoogle Scholar
  49. FumoG, AkinC, MetcalfeDD, NeckersL(2004)17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood103:1078–1084PubMedGoogle Scholar
  50. Funderburk SF, Shatkina L, Mink S, Weis Q, Weg-Remers S, Cato AC (2008) Specific N-terminal mutations in the human androgen receptor induce cytotoxicity. Neurobiol AgingGoogle Scholar
  51. GioeliD, FicarroSB, KwiekJJ, AaronsonD, HancockM, CatlingAD, WhiteFM, ChristianRE, SettlageRE, ShabanowitzJ, HuntDF, WeberMJ(2002)Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem277:29304–29314PubMedGoogle Scholar
  52. GioeliD, BlackBE, GordonV, SpencerA, KeslerCT, EblenST, PaschalBM, WeberMJ(2006)Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol20:503–515PubMedGoogle Scholar
  53. GiovannucciE, StampferMJ, KrithivasK, BrownM, DahlD, BrufskyA, TalcottJ, HennekensCH, KantoffPW(1997)The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A94:3320–3323PubMedGoogle Scholar
  54. GoreSD, CarducciMA(2000)Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs9:2923–2934PubMedGoogle Scholar
  55. GottliebB, BeitelLK, WuJH, TrifiroM(2004)The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat23:527–533PubMedGoogle Scholar
  56. GrbovicOM, BassoAD, SawaiA, YeQ, FriedlanderP, SolitD, RosenN(2006)V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A103:57–62PubMedGoogle Scholar
  57. GregoryCW, HeB, JohnsonRT, ForsdOH, MohlerJL, FrenchFS, WilsonEM(2001)A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res61:4315–4319PubMedGoogle Scholar
  58. GregoryCW, FeiX, PongutaLA, HeB, BillHM, FrenchFS, WilsonEM(2004)Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem279:7119–7130PubMedGoogle Scholar
  59. GrossmannME, HuangH, TindallDJ(2001)Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst93:1687–1697PubMedGoogle Scholar
  60. GuoZ, DaiB, JiangT, XuK, XieY, KimO, NesheiwatI, KongX, MelamedJ, HandrattaVD, NjarVC, BrodieAM, YuLR, VeenstraTD, ChenH, QiuY(2006)Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell10:309–319PubMedGoogle Scholar
  61. HanG, FosterBA, MistryS, BuchananG, HarrisJM, TilleyWD, GreenbergNM(2001)Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem276:11204–11213PubMedGoogle Scholar
  62. HanG, BuchananG, IttmannM, HarrisJM, YuX, DeMayoFJ, TilleyW, GreenbergNM(2005)Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A102:1151–1156PubMedGoogle Scholar
  63. HeB, WilsonEM(2003)Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Mol Cell Biol23:2135–2150PubMedGoogle Scholar
  64. HeB, KemppainenJA, WilsonEM(2000)FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem275:22986–22994PubMedGoogle Scholar
  65. HeB, BowenNT, MingesJT, WilsonEM(2001)Androgen-induced NH2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem276:42293–42301PubMedGoogle Scholar
  66. HeB, BaiS, HnatAT, KalmanRI, MingesJT, PattersonC, WilsonEM(2004a)An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J Biol Chem279:30643–30653Google Scholar
  67. HeB, GampeRT, Jr, KoleAJ, HnatAT, StanleyTB, AnG, StewartEL, KalmanRI, MingesJT, WilsonEM(2004b)Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell16:425–438Google Scholar
  68. HeB, GampeRT, Jr, HnatAT, FaggartJL, MingesJT, FrenchFS, WilsonEM(2006)Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity. J Biol Chem281:6648–6663PubMedGoogle Scholar
  69. HeathEI, GaskinsM, PitotHC, PiliR, TanW, MarschkeR, LiuG, HillmanD, SarkarF, ShengS, ErlichmanC, IvyP(2005)A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer4:138–141PubMedGoogle Scholar
  70. HobischA, CuligZ, RadmayrC, BartschG, KlockerH, HittmairA(1995)Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res55:3068–3072PubMedGoogle Scholar
  71. HsingAW, GaoYT, WuG, WangX, DengJ, ChenYL, SesterhennIA, MostofiFK, BenichouJ, ChangC(2000)Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res60:5111–5116PubMedGoogle Scholar
  72. HyytinenER, HaapalaK, ThompsonJ, LappalainenI, RoihaM, RantalaI, HelinHJ, JanneOA, VihinenM, PalvimoJJ, KoivistoPA(2002)Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest82:1591–1598PubMedGoogle Scholar
  73. IkonenT, PalvimoJJ, JanneOA(1997)Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem272:29821–29828PubMedGoogle Scholar
  74. IrvineRA, YuMC, RossRK, CoetzeeGA(1995)The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res55:1937–1940PubMedGoogle Scholar
  75. JensterG, van der KorputHA, van VroonhovenC, Van Der KwastTH, TrapmanJ, BrinkmannAO(1991)Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol5:1396–1404PubMedGoogle Scholar
  76. JensterG, van der KorputHA, TrapmanJ, BrinkmannAO(1995)Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem270:7341–7346PubMedGoogle Scholar
  77. JinB, BeilinJ, ZajacJ, HandelsmanDJ(2000)Androgen receptor gene polymorphism and prostate zonal volumes in Australian and Chinese men. J Androl21:91–98PubMedGoogle Scholar
  78. KamalA, ThaoL, SensintaffarJ, ZhangL, BoehmMF, FritzLC, BurrowsFJ(2003)A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature425:407–410PubMedGoogle Scholar
  79. KellyWK, SlovinS, ScherHI(1997)Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am24:421–431PubMedGoogle Scholar
  80. KellyWK, RichonVM, O'ConnorO, CurleyT, MacGregor-CurtelliB, TongW, KlangM, SchwartzL, RichardsonS, RosaE, DrobnjakM, Cordon-CordoC, ChiaoJH, RifkindR, MarksPA, ScherH(2003)Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res9:3578–3588PubMedGoogle Scholar
  81. KemppainenJA, LangleyE, WongCI, BobseineK, KelceWR, WilsonEM(1999)Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol13:440–454PubMedGoogle Scholar
  82. KnellerDG, CohenFE, LangridgeR(1990)Improvements in protein secondary structure prediction by an enhanced neural network. J Mol Biol214:171–182PubMedGoogle Scholar
  83. KoYJ, DeviGR, LondonCA, KayasA, ReddyMT, IversenPL, BubleyGJ, BalkSP(2004)Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol172:1140–1144PubMedGoogle Scholar
  84. KumarR, BetneyR, LiJ, ThompsonEB, McEwanIJ(2004)Induced alpha-helix structure in AF1 of the androgen receptor upon binding transcription factor TFIIF. Biochemistry43:3008–3013PubMedGoogle Scholar
  85. KuratsukuriK, SugimuraK, HarimotoK, KawashimaH, KishimotoT(1999)“Decoy” of androgen-responsive element induces apoptosis in LNCaP cells. Prostate41:121–126PubMedGoogle Scholar
  86. LaiJ, KeddaMA, HinzeK, SmithRL, YaxleyJ, SpurdleAB, MorrisCP, HarrisJ, ClementsJA(2007)PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis28:1032–1039PubMedGoogle Scholar
  87. LattoufJB, SrinivasanR, PintoPA, LinehanWM, NeckersL(2006)Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat Clin Pract Urol3:590–601PubMedGoogle Scholar
  88. LaveryDN, McEwanIJ(2008a)Functional characterization of the native NH2-terminal transactivation domain of the human androgen receptor: binding kinetics for interactions with TFIIF and SRC-1a. Biochemistry47:3352–3359Google Scholar
  89. LaveryDN, McEwanIJ(2008b)Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. Biochemistry47:3360–3369Google Scholar
  90. LiJ, FuJ, ToumazouC, YoonHG, WongJ(2006)A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol Endocrinol20:776–785PubMedGoogle Scholar
  91. LinHK, YehS, KangHY, ChangC(2001)Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A98:7200–7205PubMedGoogle Scholar
  92. MaH, HongH, HuangSM, IrvineRA, WebbP, KushnerPJ, CoetzeeGA, StallcupMR(1999)Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol19:6164–6173PubMedGoogle Scholar
  93. MahajanNP, LiuY, MajumderS, WarrenMR, ParkerCE, MohlerJL, EarpHS, WhangYE(2007)Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A104:8438–8443PubMedGoogle Scholar
  94. MarcelliM, IttmannM, MarianiS, SutherlandR, NigamR, MurthyL, ZhaoY, DiConciniD, PuxedduE, EsenA, EasthamJ, WeigelNL, LambDJ(2000)Androgen receptor mutations in prostate cancer. Cancer Res60:944–949PubMedGoogle Scholar
  95. MarksP, RifkindRA, RichonVM, BreslowR, MillerT, KellyWK(2001)Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer1:194–202PubMedGoogle Scholar
  96. MarroccoDL, TilleyWD, Bianco-MiottoT, EvdokiouA, ScherHI, RifkindRA, MarksPA, RichonVM, ButlerLM(2007)Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther6:51–60PubMedGoogle Scholar
  97. MatiasPM, DonnerP, CoelhoR, ThomazM, PeixotoC, MacedoS, OttoN, JoschkoS, ScholzP, WeggA, BaslerS, SchaferM, EgnerU, CarrondoMA(2000)Structural evidence for ligand specificity in the binding domain of the human androgen receptor: implications for pathogenic gene mutations. J Biol Chem275:26164–26171PubMedGoogle Scholar
  98. MoilanenAM, PoukkaH, KarvonenU, HakliM, JanneOA, PalvimoJJ(1998)Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol Cell Biol18:5128–5139PubMedGoogle Scholar
  99. MoilanenAM, KarvonenU, PoukkaH, YanW, ToppariJ, JanneOA, PalvimoJJ(1999)A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins. J Biol Chem274:3700–3704PubMedGoogle Scholar
  100. MongeA, JaglaM, LapougeG, SasorithS, CruchantM, WurtzJM, JacqminD, BergeratJP, CeralineJ(2006)Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer. Cell Mol Life Sci63:487–497PubMedGoogle Scholar
  101. NazarethLV, WeigelNL(1996)Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem271:19900–19907PubMedGoogle Scholar
  102. NickolsNG, DervanPB(2007)Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A104:10418–10423PubMedGoogle Scholar
  103. PalazzoloI, GliozziA, RusminiP, SauD, CrippaV, SimoniniF, OnestoE, BolzoniE, PolettiA(2008)The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol108:245–253PubMedGoogle Scholar
  104. PalvimoJJ, KallioPJ, IkonenT, MehtoM, JanneOA(1993)Dominant negative regulation of trans-activation by the rat androgen receptor: roles of the N-terminal domain and heterodimer formation. Mol Endocrinol7:1399–1407PubMedGoogle Scholar
  105. PlatzEA, GiovannucciE, DahlDM, KrithivasK, HennekensCH, BrownM, StampferMJ, KantoffPW(1998)The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomarkers Prev7:379–384PubMedGoogle Scholar
  106. PlatzEA, RimmEB, WillettWC, KantoffPW, GiovannucciE(2000)Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst92:2009–2017PubMedGoogle Scholar
  107. PoujolN, LobaccaroJM, ChicheL, LumbrosoS, SultanC(1997)Functional and structural analysis of R607Q and R608K androgen receptor substitutions associated with male breast cancer. Mol Cell Endocrinol130:43–51PubMedGoogle Scholar
  108. PowersMV, WorkmanP(2006)Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer13Suppl1:S125–S135PubMedGoogle Scholar
  109. PrattWB, ToftDO(1997)Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev18:306–360PubMedGoogle Scholar
  110. PrattWB, GalignianaMD, HarrellJM, DeFrancoDB(2004)Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal16:857–872PubMedGoogle Scholar
  111. QuarmbyVE, BeckmanWCJ, CookeDB, LubahnDB, JosephDR, WilsonEM, FrenchFS(1990)Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res50:735–739PubMedGoogle Scholar
  112. QuigleyCA, De BellisA, MarschkeKB, el-AwadyMK, WilsonEM, FrenchFS(1995)Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev16:271–321PubMedGoogle Scholar
  113. RadpourR, RezaeeM, TavasolyA, SolatiS, SalekiA(2007)Association of long polyglycine tracts (GGN repeats) in exon 1 of the androgen receptor gene with cryptorchidism and penile hypospadias in Iranian patients. J Androl28:164–169PubMedGoogle Scholar
  114. ReidJ, KellySM, WattK, PriceNC, McEwanIJ(2002)Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein–protein interactions. J Biol Chem277:20079–20086PubMedGoogle Scholar
  115. ReidJ, BetneyR, WattK, McEwanIJ(2003)The androgen receptor transactivation domain: the interplay between protein conformation and protein–protein interactions. Biochem Soc Trans31:1042–1046PubMedGoogle Scholar
  116. RicciardelliC, JacksonMW, ChoongCS, StahlJ, MarshallVR, HorsfallDJ, TilleyWD(2008)Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate68:830–838PubMedGoogle Scholar
  117. RodriguezG, BilbaoC, RamirezR, FalconO, LeonL, ChirinoR, FalconO, Jr., DiazBP, RiveroJF, PeruchoM, Diaz-ChicoBN, Diaz-ChicoJC(2006)Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. Int J Cancer118:1420–1425PubMedGoogle Scholar
  118. RowanBG, GarrisonN, WeigelNL, O'MalleyBW(2000a)8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol20:8720–8730Google Scholar
  119. RowanBG, WeigelNL, O'MalleyBW(2000b)Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem275:4475–4483Google Scholar
  120. SackJS, KishKF, WangC, AttarRM, KieferSE, AnY, WuGY, SchefflerJE, SalvatiME, KrystekSR, WeinmannR, EinspahrHM(2001)Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A98:4904–4909PubMedGoogle Scholar
  121. SanchezD, RosellD, HonoratoB, LopezJ, ArocenaJ, SanzG(2006)Androgen receptor mutations are associated with Gleason score in localized prostate cancer. BJU Int98:1320–1325PubMedGoogle Scholar
  122. SaporitaAJ, AiJ, WangZ(2007)The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate67:509–520PubMedGoogle Scholar
  123. SartorO, ZhengQ, EasthamJA(1999)Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology53:378–380PubMedGoogle Scholar
  124. ScherHI, BuchananG, GeraldW, ButlerLM, TilleyWD(2004)Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer11:459–476PubMedGoogle Scholar
  125. SchoenbergMP, HakimiJM, WangS, BovaGS, EpsteinJI, FischbeckKH, IsaacsWB, WalshPC, BarrackER(1994)Microsatellite mutation (CAG24–>18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun198:74–80PubMedGoogle Scholar
  126. SchulteTW, AkinagaS, SogaS, SullivanW, StensgardB, ToftD, NeckersLM(1998)Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones3:100–108PubMedGoogle Scholar
  127. SegnitzB, GehringU(1997)The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J Biol Chem272:18694–18701PubMedGoogle Scholar
  128. ShenHC, BuchananG, ButlerLM, PrescottJ, HendersonM, TilleyWD, CoetzeeGA(2005)GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biol Chem386:69–74PubMedGoogle Scholar
  129. SolitDB, ZhengFF, DrobnjakM, MunsterPN, HigginsB, VerbelD, HellerG, TongW, Cordon-CardoC, AgusDB, ScherHI, RosenN(2002)17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res8:986–993PubMedGoogle Scholar
  130. SolitDB, ScherHI, RosenN(2003)Hsp90 as a therapeutic target in prostate cancer. Semin Oncol30:709–716PubMedGoogle Scholar
  131. SpurdleAB, DiteGS, ChenX, MayneCJ, SoutheyMC, BattenLE, ChyH, TruteL, McCredieMR, GilesGG, ArmesJ, VenterDJ, HopperJL, Chenevix-TrenchG(1999)Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst91:961–966PubMedGoogle Scholar
  132. StanfordJL, JustJJ, GibbsM, WicklundKG, NealCL, BlumensteinBA, OstranderEA(1997)Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res57:1194–1198PubMedGoogle Scholar
  133. TakayamaK, KaneshiroK, TsutsumiS, Horie-InoueK, IkedaK, UranoT, IjichiN, OuchiY, ShirahigeK, AburataniH, InoueS(2007)Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene26:4453–4463PubMedGoogle Scholar
  134. TepperCG, BoucherDL, RyanPE, MaAH, XiaL, LeeLF, PretlowTG, KungHJ(2002)Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res62:6606–6614PubMedGoogle Scholar
  135. ThorntonJW, KelleyDB(1998)Evolution of the androgen receptor: structure-function implications. Bioessays20:860–869PubMedGoogle Scholar
  136. TilleyWD, WilsonCM, MarcelliM, McPhaulMJ(1990)Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res50:5382–5386PubMedGoogle Scholar
  137. TilleyWD, BuchananG, HickeyTE, BentelJM(1996)Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res2:277–285PubMedGoogle Scholar
  138. UedaT, BruchovskyN, SadarMD(2002a)Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem277:7076–7085Google Scholar
  139. UedaT, MawjiNR, BruchovskyN, SadarMD(2002b)Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem277:38087–38094Google Scholar
  140. van RoyenME, CunhaSM, BrinkMC, MatternKA, NiggAL, DubbinkHJ, VerschurePJ, TrapmanJ, HoutsmullerAB(2007)Compartmentalization of androgen receptor protein–protein interactions in living cells. J Cell Biol177:63–72PubMedGoogle Scholar
  141. VeldscholteJ, BerrevoetsCA, BrinkmannAO, GrootegoedJA, MulderE(1992)Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry31:2393–2399PubMedGoogle Scholar
  142. WallenMJ, LinjaM, KaartinenK, SchleutkerJ, VisakorpiT(1999)Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol189:559–563PubMedGoogle Scholar
  143. WangQ, LiW, LiuXS, CarrollJS, JanneOA, KeetonEK, ChinnaiyanAM, PientaKJ, BrownM(2007)A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell27:380–392PubMedGoogle Scholar
  144. WatanabeM, UshijimaT, ShiraishiT, YataniR, ShimazakiJ, KotakeT, SugimuraT, NagaoM(1997)Genetic alterations of androgen receptor gene in Japanese human prostate cancer. Jpn J Clin Oncol27:389–393PubMedGoogle Scholar
  145. WazaM, AdachiH, KatsunoM, MinamiyamaM, SangC, TanakaF, InukaiA, DoyuM, SobueG(2005)17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med11:1088–1095PubMedGoogle Scholar
  146. WeigelNL, MooreNL(2007)Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol21:2311–2319PubMedGoogle Scholar
  147. WenY, HuMC, MakinoK, SpohnB, BartholomeuszG, YanDH, HungMC(2000)HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res60:6841–6845PubMedGoogle Scholar
  148. Werner R, Holterhus PM, Binder G, Schwarz HP, Morlot M, Struve D, Marschke C, Hiort O (2006) The A645D mutation in the hinge region of the human AR gene modulates AR activity depending on the context of the polymorphic glutamine and glycine repeats. J Clin Endocrinol Metab 101:1–10Google Scholar
  149. WhitesellL, LindquistSL(2005)HSP90 and the chaperoning of cancer. Nat Rev Cancer5:761–772PubMedGoogle Scholar
  150. WurtzJM, BourguetW, RenaudJP, VivatV, ChambonP, MorasD, GronemeyerH(1996)A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol3:206PubMedGoogle Scholar
  151. YehS, LinHK, KangHY, ThinTH, LinMF, ChangC(1999)From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A96:5458–5463PubMedGoogle Scholar
  152. YongW, YangZ, PeriyasamyS, ChenH, YucelS, LiW, LinLY, WolfIM, CohnMJ, BaskinLS, SanchezER, ShouW(2007)Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J Biol Chem282:5026–5036PubMedGoogle Scholar
  153. Zegarra-MoroOL, SchmidtLJ, HuangH, TindallDJ(2002)Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res62:1008–1013PubMedGoogle Scholar
  154. ZoubeidiA, ZardanA, BeraldiE, FazliL, SoweryR, RennieP, NelsonC, GleaveM(2007)Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res67:10455–10465PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Grant Buchanan
    • 1
  • Eleanor F. Need
    • 1
  • Tina Bianco-Miotto
    • 1
  • Norman M. Greenberg
    • 1
  • Howard I. Scher
    • 1
  • Margaret M. Centenera
    • 1
  • Lisa M. Butler
    • 1
  • Diane M. Robins
    • 1
  • Wayne D. Tilley
    • 1
  1. 1.Dame Roma Mitchell Cancer Research LaboratorySchool of MedicineUniversity of Adelaide/Hanson InstituteSAAustralia

Personalised recommendations